Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent

The originally published version of this Article contained errors in Figure 4. In panel b, the square and diamond labels associated with the uppermost survival curve were incorrectly displayed as ‘n’ and ‘u’, respectively. These errors have now been corrected in both the PDF and HTML versions of the...

Full description

Bibliographic Details
Main Authors:	Pengju Wang, Xiaozhu Li, Jiwei Wang, Dongling Gao, Yuenan Li, Haoze Li, Yongchao Chu, Zhongxian Zhang, Hongtao Liu, Guozhong Jiang, Zhenguo Cheng, Shengdian Wang, Jianzeng Dong, Baisui Feng, Louisa S Chard, Nicholas R Lemoine, Yaohe Wang
Format:	Article
Language:	English
Published:	Nature Publishing Group 2018-01-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-017-02205-9

id	doaj-480ad26356494b4ba55bf572179933af
record_format	Article
spelling	doaj-480ad26356494b4ba55bf572179933af2021-05-11T10:04:06ZengNature Publishing GroupNature Communications2041-17232018-01-01911110.1038/s41467-017-02205-9Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agentPengju Wang0Xiaozhu Li1Jiwei Wang2Dongling Gao3Yuenan Li4Haoze Li5Yongchao Chu6Zhongxian Zhang7Hongtao Liu8Guozhong Jiang9Zhenguo Cheng10Shengdian Wang11Jianzeng Dong12Baisui Feng13Louisa S Chard14Nicholas R Lemoine15Yaohe Wang16Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversityCAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of SciencesSino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversityCAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of SciencesDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversityCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of LondonSino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversitySino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou UniversityThe originally published version of this Article contained errors in Figure 4. In panel b, the square and diamond labels associated with the uppermost survival curve were incorrectly displayed as ‘n’ and ‘u’, respectively. These errors have now been corrected in both the PDF and HTML versions of the Article.https://doi.org/10.1038/s41467-017-02205-9
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Pengju Wang Xiaozhu Li Jiwei Wang Dongling Gao Yuenan Li Haoze Li Yongchao Chu Zhongxian Zhang Hongtao Liu Guozhong Jiang Zhenguo Cheng Shengdian Wang Jianzeng Dong Baisui Feng Louisa S Chard Nicholas R Lemoine Yaohe Wang
spellingShingle	Pengju Wang Xiaozhu Li Jiwei Wang Dongling Gao Yuenan Li Haoze Li Yongchao Chu Zhongxian Zhang Hongtao Liu Guozhong Jiang Zhenguo Cheng Shengdian Wang Jianzeng Dong Baisui Feng Louisa S Chard Nicholas R Lemoine Yaohe Wang Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent Nature Communications
author_facet	Pengju Wang Xiaozhu Li Jiwei Wang Dongling Gao Yuenan Li Haoze Li Yongchao Chu Zhongxian Zhang Hongtao Liu Guozhong Jiang Zhenguo Cheng Shengdian Wang Jianzeng Dong Baisui Feng Louisa S Chard Nicholas R Lemoine Yaohe Wang
author_sort	Pengju Wang
title	Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
title_short	Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
title_full	Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
title_fullStr	Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
title_full_unstemmed	Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
title_sort	author correction: re-designing interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
publisher	Nature Publishing Group
series	Nature Communications
issn	2041-1723
publishDate	2018-01-01
description	The originally published version of this Article contained errors in Figure 4. In panel b, the square and diamond labels associated with the uppermost survival curve were incorrectly displayed as ‘n’ and ‘u’, respectively. These errors have now been corrected in both the PDF and HTML versions of the Article.
url	https://doi.org/10.1038/s41467-017-02205-9
work_keys_str_mv	AT pengjuwang authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT xiaozhuli authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT jiweiwang authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT donglinggao authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT yuenanli authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT haozeli authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT yongchaochu authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT zhongxianzhang authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT hongtaoliu authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT guozhongjiang authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT zhenguocheng authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT shengdianwang authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT jianzengdong authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT baisuifeng authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT louisaschard authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT nicholasrlemoine authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent AT yaohewang authorcorrectionredesigninginterleukin12toenhanceitssafetyandpotentialasanantitumorimmunotherapeuticagent
_version_	1721448719320088576

Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent

Similar Items